SOME ASPECTS OF THE USE OF OSTEOMODIFIERS IN ONCOLOGY PATIENTS

MAIA SHANIDZE; VERA KHUNDZAKISHVILI; LANA KEBURIA

doi:10.52340/jecm.2025.06.20

SOME ASPECTS OF THE USE OF OSTEOMODIFIERS IN ONCOLOGY PATIENTS

Authors

MAIA SHANIDZE
VERA KHUNDZAKISHVILI
LANA KEBURIA

DOI:

https://doi.org/10.52340/jecm.2025.06.20

Keywords:

Osteomodifiers, bisphosphonates, denosumab, oncology patients

Abstract

During the use of the osteomodifier denosumab in oncology patients of various ages and diagnoses, a complication in the oral cavity-necrosis of the jaw bone was recorded in 3.5% of cases. No other changes and acute reactions in the oral cavity were detected against of taking the drug.

Downloads

Download data is not yet available.

References

Ласкарис Дж. Лечение заболеваний слизистой оболочки рта:Руководство для врачей. 2006.

Лукиных Л.М. Заболевания слизистой оболочки полости рта. 2000. 367с.

Лукиных Л.М., Тиунова Н.В. Проблемы стоматологии, 2011.

Roodman D. Mechanisms of bone metastasis, N Eng J Med.2004.

Kozlow W. Guise TA. Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy. J Mammary Gland Biol Neoplasia.2005.10 169-180.

Rizzoli R. Akesson K. Bouxsein M. et. al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011.373-390.

Rosen L.S., Gordon D, Kaminski M. et.al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 2003. 98.

M.L. Wade and J.B. Suzuki. Issues related to diagnosis and treatment nate-induced osteonecrosis of the Jaws. Grand Rounds Oral Sist.

Saad F. Gleason DM. Murray R. et. al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl CancerInst.2002.94.

Wade M.L., Suzuki J.B. Issues related to diagnosis and treatment of bisphosphonate=induced osteonecrosis of the jaws. Grand Rounds Oral Syst Med, 2007.

Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза-применение моноклональных человеческих антител к RANKL (Денозумаб), Остеопороз и остеопатии. 2011. Е14. №2.

Никитинская О.А., Торопцова Н.В. Денозумаб-первый генно-инженерный препарат для лечения остеопороза. ж.Современная ревматология.2011. №3, 12.

Thosani S, Hu Ml. Denozumab: a new agent in the management of hypercalcemia of malignancy. Future Oncology.2015,11(21).

Reid IR, Miller PD, Brown JP et.al. Effects of denosumab on bone histomorphometry: The freedom and stand studies. J. Bone Miner Res.2010.25(10).

Okada N. Kawazoe K. Teraoka K. et.al. Identification of the Risk Factors Associated with Hypocalcemia Induced by Denosumab. Bio Pharm Bull.2013.36(10).

Hadji P. Cancer Treatment-Induced Bone loss in women with breast cancer. Bone Key Reports.2015,4.

Багрова С.Г. Бисфосфонаты и деносумаб, в чем отличия? RosOncoWeb. 17.05.2023.